-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Solid Tumor Drug Details: ERAS-601 is under development for...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-007
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-007 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Pancreatic Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Gastric Cancer Drug Details: ERAS-601 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Non-Small Cell Lung Cancer Drug Details: ERAS-601 is...
-
Thematic Analysis
NewArtificial Intelligence – Executive Briefing (Third Edition) – Thematic Intelligence
Artificial Intelligence (AI) Thematic Report Overview The AI market is forecast to grow at a CAGR of more than 38% between 2023 and 2030. The recent success of OpenAI’s ChatGPT has influenced most of the tech giants to realign their AI priorities. While some of them have been already working on the underlying technology i.e., generative AI (GenAI), they are now rushing for an edge in the new AI era with a flurry of initiatives. The competitive landscape is evolving...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-15025 in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-15025 in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-15025 in Esophageal Cancer Drug Details: BGB-15025 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBP-1008 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBP-1008 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBP-1008 in Triple-Negative Breast Cancer (TNBC) Drug Details: CBP-1008...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s ERAS-601
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-601 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.